Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 149896
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 109
  • list Pharmaceuticals and Healthcare

PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.

Scope of the Report:

The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.

The worldwide market for PARP (Poly ADP-Ribose Polymerase) Inhibitor is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

This report focuses on the PARP (Poly ADP-Ribose Polymerase) Inhibitor in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

Tesaro

Clovis Oncology

AstraZeneca

Abbvie

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Lynparza

Diraparib

Rucaparib

Talazoparib

Others

Market Segment by Applications, can be divided into

Hospitals

Pharmacial

Retail

Online

There are 15 Chapters to deeply display the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market.

Chapter 1, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, with sales, revenue, and price of PARP (Poly ADP-Ribose Polymerase) Inhibitor, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of PARP (Poly ADP-Ribose Polymerase) Inhibitor, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, PARP (Poly ADP-Ribose Polymerase) Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Introduction

1.2 Market Analysis by Type

1.2.1 Lynparza

1.2.2 Diraparib

1.2.3 Rucaparib

1.2.4 Talazoparib

1.2.5 Others

1.3 Market Analysis by Applications

1.3.1 Hospitals

1.3.2 Pharmacial

1.3.3 Retail

1.3.4 Online

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Tesaro

2.1.1 Business Overview

2.1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Clovis Oncology

2.2.1 Business Overview

2.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 AstraZeneca

2.3.1 Business Overview

2.3.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Abbvie

2.4.1 Business Overview

2.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Abbvie PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Manufacturer (2016-2017)

3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2017

3.3.2 Top 6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Analysis by Regions

4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Regions

4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Regions (2013-2018)

4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Regions (2013-2018)

4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

4.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

4.5 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

5 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries

5.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Countries

5.1.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Countries (2013-2018)

5.1.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Countries (2013-2018)

5.2 United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

5.3 Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

5.4 Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

6 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries

6.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Countries

6.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Countries (2013-2018)

6.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Countries (2013-2018)

6.2 Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

6.3 UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

6.4 France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

6.5 Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

6.6 Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

7 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries

7.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Countries (2013-2018)

7.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

7.3 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

7.4 Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

7.5 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

7.6 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

8 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries

8.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Countries

8.1.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Countries (2013-2018)

8.1.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Countries (2013-2018)

8.2 Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

8.3 Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

8.4 Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

9 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries

9.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

9.3 UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

9.4 Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

9.5 Nigeria PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

9.6 South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2013-2018)

10 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Type

10.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Type (2013-2018)

10.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Type (2013-2018)

10.2 Lynparza Sales Growth and Price

10.2.1 Global Lynparza Sales Growth (2013-2018)

10.2.2 Global Lynparza Price (2013-2018)

10.3 Diraparib Sales Growth and Price

10.3.1 Global Diraparib Sales Growth (2013-2018)

10.3.2 Global Diraparib Price (2013-2018)

10.4 Rucaparib Sales Growth and Price

10.4.1 Global Rucaparib Sales Growth (2013-2018)

10.4.2 Global Rucaparib Price (2013-2018)

10.5 Talazoparib Sales Growth and Price

10.5.1 Global Talazoparib Sales Growth (2013-2018)

10.5.2 Global Talazoparib Price (2013-2018)

10.6 Others Sales Growth and Price

10.6.1 Global Others Sales Growth (2013-2018)

10.6.2 Global Others Price (2013-2018)

11 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Application

11.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2013-2018)

11.2 Hospitals Sales Growth (2013-2018)

11.3 Pharmacial Sales Growth (2013-2018)

11.4 Retail Sales Growth (2013-2018)

11.5 Online Sales Growth (2013-2018)

12 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2018-2023)

12.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Growth Rate (2018-2023)

12.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Regions (2018-2023)

12.2.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2018-2023)

12.2.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2018-2023)

12.2.3 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2018-2023)

12.2.4 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2018-2023)

12.2.5 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2018-2023)

12.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Type (2018-2023)

12.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Type (2018-2023)

12.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share Forecast by Type (2018-2023)

12.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Application (2018-2023)

12.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Application (2018-2023)

12.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Picture

Table Product Specifications of PARP (Poly ADP-Ribose Polymerase) Inhibitor

Figure Global Sales Market Share of P

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery